Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
McKinsey
Dow
Mallinckrodt
Colorcon

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR DEXRAZOXANE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Dexrazoxane Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002827 ↗ Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease Completed Children's Cancer Group Phase 3 1996-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells. It is not yet known if chemotherapy is more effective with or without dexrazoxane for Hodgkin's disease. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy, with or without dexrazoxane, followed by radiation therapy in treating young patients with newly diagnosed stage I, stage II, or stage III Hodgkin's disease.
NCT00002827 ↗ Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease Completed National Cancer Institute (NCI) Phase 3 1996-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells. It is not yet known if chemotherapy is more effective with or without dexrazoxane for Hodgkin's disease. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy, with or without dexrazoxane, followed by radiation therapy in treating young patients with newly diagnosed stage I, stage II, or stage III Hodgkin's disease.
NCT00002827 ↗ Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease Completed Children's Oncology Group Phase 3 1996-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells. It is not yet known if chemotherapy is more effective with or without dexrazoxane for Hodgkin's disease. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy, with or without dexrazoxane, followed by radiation therapy in treating young patients with newly diagnosed stage I, stage II, or stage III Hodgkin's disease.
NCT00003667 ↗ Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma Completed National Cancer Institute (NCI) Phase 2 1998-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy with biological therapy may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy with or without biological therapy in treating patients who have newly diagnosed high-risk Ewing's sarcoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dexrazoxane Hydrochloride

Condition Name

Condition Name for Dexrazoxane Hydrochloride
Intervention Trials
Sarcoma 9
Cardiac Toxicity 7
Acute Myeloid Leukemia 6
Acute Lymphoblastic Leukemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dexrazoxane Hydrochloride
Intervention Trials
Leukemia 17
Sarcoma 12
Precursor Cell Lymphoblastic Leukemia-Lymphoma 12
Leukemia, Lymphoid 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dexrazoxane Hydrochloride

Trials by Country

Trials by Country for Dexrazoxane Hydrochloride
Location Trials
United States 575
Canada 72
Australia 22
Puerto Rico 11
New Zealand 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dexrazoxane Hydrochloride
Location Trials
Texas 25
New York 24
California 21
Massachusetts 20
Tennessee 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dexrazoxane Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Dexrazoxane Hydrochloride
Clinical Trial Phase Trials
Phase 3 18
Phase 2/Phase 3 2
Phase 2 17
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dexrazoxane Hydrochloride
Clinical Trial Phase Trials
Completed 21
Terminated 14
Recruiting 11
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dexrazoxane Hydrochloride

Sponsor Name

Sponsor Name for Dexrazoxane Hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 27
Children's Oncology Group 12
Dana-Farber Cancer Institute 6
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dexrazoxane Hydrochloride
Sponsor Trials
Other 68
NIH 27
Industry 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Colorcon
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.